The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is seeking participants for the HEALER portfolio, a next-generation host-directed medical countermeasure initiative. The goal of the HEALER portfolio is to create a new generation of therapeutics that enable the host to recover from physiological impacts and maintain operational effectiveness even under duress. The program focuses on delivering medical countermeasures that provide layered physiological protection to the Warfighter by targeting one or more of the following critical host systems: neurological protection, respiratory stabilization, immune modulation, hematologic and vascular function, and cellular stress and repair pathways. • The HEALER portfolio is open to therapeutic development collaborators and drug development support collaborators. • Therapeutic development collaborators should submit a white paper that provides a comprehensive overview of their product, including its host-directed mechanism of action, physiological pathways it targets, and intended use and proposed FDA indication. • Drug development support collaborators should submit a summary of their core capabilities, relevant experience with complex biologics or small molecules, FDA regulatory experience, available infrastructure, and capacity or technology that can accelerate the development of advanced medical countermeasures for the HEALER portfolio. • The HEALER portfolio creates a viable commercial opportunity that exceeds the traditional CBRN mission space, offering a path to sustainable product development. • Collaboration with expert service providers is essential to accelerate development within the HEALER portfolio.